Payment overview · 2025
General Payments
$5,250.75
213 reported records · 22 companies
Healthcare provider profile · identity verified
Solomon N Forouzesh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · CULVER CITY, CA · NPI 1457548133
Verified facts
What the public records show
CMS Open Payments records show Solomon N Forouzesh, M.D. received $5,250.75 in general payments during 2025 across 213 reported records.
Amgen Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Benlysta, Farxiga, Otezla, Rinvoq, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Saphnelo by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Simponi by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $1,137.15 | 21.7% | 54 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,034.17 | 19.7% | 56 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $455.38 | 8.7% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $410.28 | 7.8% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $399.41 | 7.6% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $372.78 | 7.1% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $298.98 | 5.7% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $251.91 | 4.8% | 7 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $221.16 | 4.2% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $190.73 | 3.6% | 4 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $86.89 | 1.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $76.82 | 1.5% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.78 | 0.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.34 | 0.8% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $36.06 | 0.7% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $34.21 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $33.63 | 0.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.63 | 0.6% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $26.53 | 0.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.31 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.80 | 0.5% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $23.80 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,250.75 | 213 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $508.46 | 20 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $499.13 | 24 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $378.59 | 10 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $363.03 | 13 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $298.98 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $283.22 | 10 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $251.91 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $247.19 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $242.29 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $242.17 | 17 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $221.16 | 10 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $209.07 | 12 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $199.48 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $193.92 | 7 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $190.73 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $187.86 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $151.03 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $144.64 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.63 | 6 | 2025 |
Source payment records
|
|||||
| AMJEVITA Normalized: amjevita |
Biological | Amgen Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $76.82 | 2 | 2025 |
Source payment records
|
|||||
| HUMIRA Normalized: humira |
Biological | ABBVIE INC. | $52.34 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.81 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| Adalimumab-aacf Normalized: adalimumab aacf |
Biological | Fresenius Kabi USA, LLC | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| SOVUNA Normalized: sovuna |
Drug | ANI Pharmaceuticals, Inc. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
58 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 532 | 146 |
| Simvastatin | Simvastatin | 325 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 76 |
| Methotrexate | Methotrexate Sodium | 291 | 74 |
| Famotidine | Famotidine | 270 | 91 |
| Gabapentin | Gabapentin | 244 | 65 |
| Prednisone | Prednisone | 209 | 59 |
| Metformin Hcl | Metformin Hcl | 201 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 31 |
| Omeprazole | Omeprazole | 167 | 50 |
| Tramadol Hcl | Tramadol Hcl | 160 | 38 |
| Lisinopril | Lisinopril | 152 | 34 |
| Ozempic | Semaglutide | 151 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 142 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 59 |
| Farxiga | Dapagliflozin Propanediol | 136 | 40 |
| Ibuprofen | Ibuprofen | 135 | 48 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 128 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 127 | 42 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 120 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 38 |
| Azithromycin | Azithromycin | 114 | 80 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 114 | 38 |
| Potassium Chloride | Potassium Chloride | 103 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 33 |
| Rinvoq | Upadacitinib | 99 | 15 |
| Alprazolam | Alprazolam | 98 | 17 |
| Metformin Hcl Er | Metformin Hcl | 97 | 32 |
| Repatha Sureclick | Evolocumab | 90 | 19 |
| Losartan Potassium | Losartan Potassium | 89 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 24 |
| Enbrel Sureclick | Etanercept | 88 | 18 |
| Folic Acid | Folic Acid | 83 | 30 |
| Pregabalin | Pregabalin | 82 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 68 |
| Lidocaine | Lidocaine | 79 | 33 |
| Lorazepam | Lorazepam | 79 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 29 |
| Rybelsus | Semaglutide | 72 | 20 |
| Methylprednisolone | Methylprednisolone | 71 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Memantine Hcl | Memantine Hcl | 67 | 16 |
| Furosemide | Furosemide | 62 | 23 |
| Benlysta | Belimumab | 59 | suppressed |
| Prolia | Denosumab | 58 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 15 |
| Humira(Cf) Pen | Adalimumab | 55 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 12 |
| Mirtazapine | Mirtazapine | 53 | 14 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Orencia | Abatacept | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Allopurinol | Allopurinol | 44 | 17 |
| Colchicine | Colchicine | 44 | 19 |
| Atenolol | Atenolol | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 31 |
| Hydrocortisone | Hydrocortisone | 41 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 13 |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 39 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 15 |
| Topiramate | Topiramate | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 19 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 14 |
| Simponi | Golimumab | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 14 |
| Cimzia (2 Pack) | Certolizumab Pegol | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Leflunomide | Leflunomide | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 27 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Saphnelo | Anifrolumab-Fnia | 21 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Forteo | Teriparatide | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Rasuvo | Methotrexate/Pf | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Actemra | Tocilizumab | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Jublia | Efinaconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pennsaid | Diclofenac Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Celebrex | Celecoxib | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tavaborole | Tavaborole | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Welchol | Colesevelam Hcl | 12 | suppressed |
| Zetia | Ezetimibe | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Zyprexa | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,250.75 · 213 records | Amgen Inc. | ACTHAR, AIRSUPRA, AMJEVITA, Actemra, Adalimumab-aacf, BENLYSTA, BLINCYTO, Bimzelx, COSENTYX, CRYSVITA, ENBREL, EVENITY, FARXIGA, GEMTESA, HUMIRA, KEVZARA, LUPKYNIS, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OTEZLA, QULIPTA, REPATHA, RINVOQ, SKYRIZI, SOVUNA, STRENSIQ, TALTZ, TAVNEOS, TRELEGY ELLIPTA, TREMFYA, UBRELVY, UPLIZNA, Wegovy, XELJANZ, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error